Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Bristol, Exelixis Trials Preview Changes In Kidney Cancer Market

This article was originally published in The Pink Sheet Daily

Executive Summary

Commenting on pivotal trial success for Bristol’s checkpoint immunotherapy Opdivo and targeted Cometriq in renal cancer, Exelixis CEO Michael Morrissey says there’s room for two new different drugs for kidney cancer, and points out that an early stage study combining them is under way.


Related Content

Cometriq Thyroid Approval May Open Door For Use In Prostate Cancer


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts